Targeted therapeutic intervention in RCC aims at specific components of either the AKT/mammalian target of rapamycin (mTOR) or the mitogen-activated protein kinase (MAPK) pathways, together providing hypoxia-related signal transduction in RCC 35. This evidence concerns the gene AKT1 and renal cell carcinoma.